Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer

Affiliations

• ¹ Department of Radiation Oncology, University of California, Los Angeles, California.
• ² Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, California.
• ³ Department of Medicine, University of California, Los Angeles, California.
• ⁴ Department of Surgery, Division of Thoracic Surgery, University of California, Los Angeles, California.
• ⁵ Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado.
• ⁶ Department of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado.
• ⁷ Department of Radiation Oncology, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
• ⁸ Department of Medical Oncology, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
• ⁹ Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
• ¹⁰ Department of Radiation Oncology, City of Hope, Los Angeles, California. Electronic address: PercyLee@coh.org.